Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huaier Granules for Immunotherapy/Anti-angiogenic Therapy–Associated Proteinuria in Breast Cancer
ChiCTR2500109379Phase 4Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Sep 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of huaier granule in proteinuria and breast cancer (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Effective rate of proteinuria treatment after 8 weeks of Huaier Granules therapy. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
huaier granule
03
Conditions
proteinuriabreast cancer
Beyond the preview
Go deeper on ChiCTR2500109379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109379.